SecBot SecBot
Biotech Drug Report Generated Jul 10, 2026

GS-6791

NRIX·Nurix Therapeutics, Inc.
NEUTRAL
Drug Impact Rating4/10
Trial phase
Phase 1
Time to market
Estimated 6-8+ years, if successful. Still in Phase 1; inflammation/immunology programs typically take years to reach approval.
Why 4/10
GS-6791 is an early-phase (Phase 1) partnered program with Gilead. No hard dated catalyst (PDUFA or pivotal readout) is scheduled in the next ~12 months. The next milestone is Phase 1 healthy-volunteer safety data, but no timeline has been provided. Nurix's dominant value driver is its lead BTK degrader bexobrutideg (backed by a $700M Roche deal), not this IRAK4 program. Score reflects early-stage partnered asset without a near-term binary catalyst.
Actionable Insight NEUTRAL

GS-6791 is a minor piece of the NRIX story. Investors should watch for Phase 1 healthy-volunteer safety/PK data from Gilead, which could inform Nurix's decision on opting into a 50/50 U.S. profit share. However, the stock's near-term trajectory is dominated by bexobrutideg (BTK degrader) and the Roche collaboration, GS-6791 is not a standalone catalyst for NRIX.

Price Chart

Loading chart...

Executive Summary

GS-6791 (also known as NX-0479) is an oral IRAK4 protein degrader being developed by Gilead Sciences under a collaboration with Nurix Therapeutics (Nasdaq: NRIX). It is the first drug candidate to come out of the Nurix-Gilead 2019 discovery collaboration. After Gilead exercised its option in March 2023, Gilead has led all development. The FDA cleared the IND in April 2025, and a Phase 1 SAD/MAD trial in healthy volunteers began in Q2 2025. Nurix retains an option to co-develop and share U.S. profits 50/50 after Phase 1 data readout. The drug targets inflammatory conditions like rheumatoid arthritis and atopic dermatitis. For NRIX investors, GS-6791 is an early-stage partnered program, less impactful to the stock than Nurix's lead BTK degrader bexobrutideg, which recently secured a $700M Roche collaboration.

How It Works

GS-6791 is an oral drug that degrades IRAK4, a key protein inside immune cells that acts like a master switch for inflammation. By destroying IRAK4 rather than just blocking it temporarily, the drug aims to shut down inflammatory signals more thoroughly and durably. This could help treat diseases driven by excessive inflammation, such as rheumatoid arthritis and atopic dermatitis (eczema).

Trial Status

FDA cleared the IND in April 2025. Gilead initiated a Phase 1 single- and multiple-ascending dose (SAD/MAD) study in healthy volunteers in Q2 2025. Preclinical data were presented at EADV in September 2025. The Phase 1 trial is ongoing. No clinical data readout has been publicly disclosed yet.

The Two-Sided Case

▲ Bull Case4
First-in-class potential: GS-6791 is one of the few IRAK4 degraders to reach clinical testing, and degradation may achieve deeper, more sustained pathway blockade versus traditional IRAK4 kinase inhibitors, an approach Kymera/Sanofi is also pursuing (KT-485).
Large market opportunity: Targets multi-billion-dollar markets in inflammation, rheumatoid arthritis (~$25B+) and atopic dermatitis (~$10B+).
Gilead bears all development costs and has committed resources; Nurix receives a $20M option fee, up to $425M in milestones, and retains a 50/50 U.S. profit-share option after Phase 1.
Preclinical data showed near-complete IRAK4 degradation and robust efficacy in both arthritis and dermatitis mouse models, presented at ACR and EADV in 2024-2025.
▼ Bear Case4
Very early-stage (Phase 1 in healthy volunteers), clinical failure rates in Phase 1 are high, and safety/PK in humans hasn't been demonstrated yet.
Competitive landscape: Kymera Therapeutics/Sanofi have a competing IRAK4 degrader (KT-485) advancing toward the clinic, while Pfizer and others have IRAK4 kinase inhibitors in development.
Dilution risk: GS-6791 is Gilead-led; Nurix has no control over development pace or go/no-go decisions. If Phase 1 data disappoints, Gilead may halt the program.
Not a primary NRIX catalyst: Nurix's stock is driven overwhelmingly by its lead BTK degrader bexobrutideg (recent $700M Roche deal), GS-6791 moves are secondary.

Upcoming Catalysts

  • Phase 1 SAD/MAD healthy-volunteer safety, tolerability, PK/PD data readout, no firm date disclosed (likely late 2025 or 2026).
  • Nurix's decision on whether to opt into 50/50 U.S. profit share and co-development with Gilead (timed after Phase 1 data).

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Nurix Therapeutics, Inc. PRESS-RELEASE NRIX ·Originating report

Sources · 10

Hover a chip for the title
1 gilead.com2 ir.nurixtx.com3 ir.nurixtx.com4 biospace.com5 ir.nurixtx.com6 ir.nurixtx.com7 fiercebiotech.com8 clinicaltrialvanguard.com9 biospace.com10 nurixtx.com